Global Non-alcoholic Steatohepatitis Market Size, Status and Forecast 2019-2025

Published On: Jun 2019

Format: PDF

Publisher: QY Research

Pages: 91

Report ID: 1175

Non-alcoholic steatohepatitis (NASH), is a common liver disease, often called as silent liver disease. It is asymptomatic until its later stages, and thus many patients are unaware of their condition.
NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.
In 2018, the global Non-alcoholic Steatohepatitis market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Non-alcoholic Steatohepatitis status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Non-alcoholic Steatohepatitis development in United States, Europe and China.

The key players covered in this study
GENFIT
Gilead Sciences (GILD)
AstraZeneca
Novartis
Bristol-Myers Squibb Company
Allergan
Novo Nordisk
Boehringer Ingelheim
Pfizer

Market segment by Type, the product can be split into
Serum biomarkers
Hepatic fibrosis biomarkers
Apoptosis biomarkers
Oxidative stress biomarkers
Others

Market segment by Application, split into
Pharma & CRO Industry
Hospitals
Diagnostic Labs
Academic Research Institutes

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Non-alcoholic Steatohepatitis status, future forecast, growth opportunity, key market and key players.
To present the Non-alcoholic Steatohepatitis development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Non-alcoholic Steatohepatitis are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Non-alcoholic Steatohepatitis Market Size Growth Rate by Type (2014-2025)
1.4.2 Serum biomarkers
1.4.3 Hepatic fibrosis biomarkers
1.4.4 Apoptosis biomarkers
1.4.5 Oxidative stress biomarkers
1.4.6 Others
1.5 Market by Application
1.5.1 Global Non-alcoholic Steatohepatitis Market Share by Application (2014-2025)
1.5.2 Pharma & CRO Industry
1.5.3 Hospitals
1.5.4 Diagnostic Labs
1.5.5 Academic Research Institutes
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Non-alcoholic Steatohepatitis Market Size
2.2 Non-alcoholic Steatohepatitis Growth Trends by Regions
2.2.1 Non-alcoholic Steatohepatitis Market Size by Regions (2014-2025)
2.2.2 Non-alcoholic Steatohepatitis Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Non-alcoholic Steatohepatitis Market Size by Manufacturers
3.1.1 Global Non-alcoholic Steatohepatitis Revenue by Manufacturers (2014-2019)
3.1.2 Global Non-alcoholic Steatohepatitis Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Non-alcoholic Steatohepatitis Market Concentration Ratio (CR5 and HHI)
3.2 Non-alcoholic Steatohepatitis Key Players Head office and Area Served
3.3 Key Players Non-alcoholic Steatohepatitis Product/Solution/Service
3.4 Date of Enter into Non-alcoholic Steatohepatitis Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Non-alcoholic Steatohepatitis Market Size by Type (2014-2019)
4.2 Global Non-alcoholic Steatohepatitis Market Size by Application (2014-2019)

5 United States
5.1 United States Non-alcoholic Steatohepatitis Market Size (2014-2019)
5.2 Non-alcoholic Steatohepatitis Key Players in United States
5.3 United States Non-alcoholic Steatohepatitis Market Size by Type
5.4 United States Non-alcoholic Steatohepatitis Market Size by Application

6 Europe
6.1 Europe Non-alcoholic Steatohepatitis Market Size (2014-2019)
6.2 Non-alcoholic Steatohepatitis Key Players in Europe
6.3 Europe Non-alcoholic Steatohepatitis Market Size by Type
6.4 Europe Non-alcoholic Steatohepatitis Market Size by Application

7 China
7.1 China Non-alcoholic Steatohepatitis Market Size (2014-2019)
7.2 Non-alcoholic Steatohepatitis Key Players in China
7.3 China Non-alcoholic Steatohepatitis Market Size by Type
7.4 China Non-alcoholic Steatohepatitis Market Size by Application

8 Japan
8.1 Japan Non-alcoholic Steatohepatitis Market Size (2014-2019)
8.2 Non-alcoholic Steatohepatitis Key Players in Japan
8.3 Japan Non-alcoholic Steatohepatitis Market Size by Type
8.4 Japan Non-alcoholic Steatohepatitis Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Non-alcoholic Steatohepatitis Market Size (2014-2019)
9.2 Non-alcoholic Steatohepatitis Key Players in Southeast Asia
9.3 Southeast Asia Non-alcoholic Steatohepatitis Market Size by Type
9.4 Southeast Asia Non-alcoholic Steatohepatitis Market Size by Application

10 India
10.1 India Non-alcoholic Steatohepatitis Market Size (2014-2019)
10.2 Non-alcoholic Steatohepatitis Key Players in India
10.3 India Non-alcoholic Steatohepatitis Market Size by Type
10.4 India Non-alcoholic Steatohepatitis Market Size by Application

11 Central & South America
11.1 Central & South America Non-alcoholic Steatohepatitis Market Size (2014-2019)
11.2 Non-alcoholic Steatohepatitis Key Players in Central & South America
11.3 Central & South America Non-alcoholic Steatohepatitis Market Size by Type
11.4 Central & South America Non-alcoholic Steatohepatitis Market Size by Application

12 International Players Profiles
12.1 GENFIT
12.1.1 GENFIT Company Details
12.1.2 Company Description and Business Overview
12.1.3 Non-alcoholic Steatohepatitis Introduction
12.1.4 GENFIT Revenue in Non-alcoholic Steatohepatitis Business (2014-2019)
12.1.5 GENFIT Recent Development
12.2 Gilead Sciences (GILD)
12.2.1 Gilead Sciences (GILD) Company Details
12.2.2 Company Description and Business Overview
12.2.3 Non-alcoholic Steatohepatitis Introduction
12.2.4 Gilead Sciences (GILD) Revenue in Non-alcoholic Steatohepatitis Business (2014-2019)
12.2.5 Gilead Sciences (GILD) Recent Development
12.3 AstraZeneca
12.3.1 AstraZeneca Company Details
12.3.2 Company Description and Business Overview
12.3.3 Non-alcoholic Steatohepatitis Introduction
12.3.4 AstraZeneca Revenue in Non-alcoholic Steatohepatitis Business (2014-2019)
12.3.5 AstraZeneca Recent Development
12.4 Novartis
12.4.1 Novartis Company Details
12.4.2 Company Description and Business Overview
12.4.3 Non-alcoholic Steatohepatitis Introduction
12.4.4 Novartis Revenue in Non-alcoholic Steatohepatitis Business (2014-2019)
12.4.5 Novartis Recent Development
12.5 Bristol-Myers Squibb Company
12.5.1 Bristol-Myers Squibb Company Company Details
12.5.2 Company Description and Business Overview
12.5.3 Non-alcoholic Steatohepatitis Introduction
12.5.4 Bristol-Myers Squibb Company Revenue in Non-alcoholic Steatohepatitis Business (2014-2019)
12.5.5 Bristol-Myers Squibb Company Recent Development
12.6 Allergan
12.6.1 Allergan Company Details
12.6.2 Company Description and Business Overview
12.6.3 Non-alcoholic Steatohepatitis Introduction
12.6.4 Allergan Revenue in Non-alcoholic Steatohepatitis Business (2014-2019)
12.6.5 Allergan Recent Development
12.7 Novo Nordisk
12.7.1 Novo Nordisk Company Details
12.7.2 Company Description and Business Overview
12.7.3 Non-alcoholic Steatohepatitis Introduction
12.7.4 Novo Nordisk Revenue in Non-alcoholic Steatohepatitis Business (2014-2019)
12.7.5 Novo Nordisk Recent Development
12.8 Boehringer Ingelheim
12.8.1 Boehringer Ingelheim Company Details
12.8.2 Company Description and Business Overview
12.8.3 Non-alcoholic Steatohepatitis Introduction
12.8.4 Boehringer Ingelheim Revenue in Non-alcoholic Steatohepatitis Business (2014-2019)
12.8.5 Boehringer Ingelheim Recent Development
12.9 Pfizer
12.9.1 Pfizer Company Details
12.9.2 Company Description and Business Overview
12.9.3 Non-alcoholic Steatohepatitis Introduction
12.9.4 Pfizer Revenue in Non-alcoholic Steatohepatitis Business (2014-2019)
12.9.5 Pfizer Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details